Our mission is to harness the power of the immune system to bring therapies with curative intent to individuals living with cancer

 

Are you a physician?
Agenus will be attending the ESMO GI
Congress 2024 in Munich, June 25 – 29.
Let’s meet to discuss the future
of immuno-oncology.

Spotlight on botensilimab

Agenus’ next-generation CTLA-4 antibody

Botensilimab was designed to:



Innovation in immunotherapy

What is immunotherapy for cancer?

Today, we can create drugs that empower the immune system to do its job – cure disease.

How does botensilimab work?

By modifying the Fc “tail” of the antibody, our scientists discovered that its efficacy and tolerability can be significantly enhanced.

By the numbers

Agenus discovers, manufactures, and develops immuno-oncology (I-O) therapeutics. Our vision is to expand the patient population benefiting from I-O through combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through subsidiary MiNK Therapeutics), adjuvants and vaccines (through subsidiary SaponiQx).

0
clinical-stage antibody programs
0 K
US patient opportunity for lead program
$ 0 B
partnership transactions
$ 0 B
annual manufacturing capacity for botensilimab at planned Emeryville site

Acceleration through partnerships

While we retain ownership in the majority of our programs, we have accelerated the development of select programs through partnerships with industry leaders. These partnerships generate capital to further support our pipeline development, and many offer optionality for future participation in development and commercialization.

Who we are

We have brought together top talent and expertise to advance our mission, building a team of employees across our offices in the US and Europe.